Author: admin

According to DelveInsight’s analysis of spinal stenosis, there were 3,674,901 diagnosed cases of spinal stenosis in the United States in 2021, and it is projected that this number will rise to around 3,998,071 by 2030. Therefore, the growing elderly population, along with age-related bodily changes, is expected to directly contribute to an increase in spinal stenosis cases.

DelveInsight’s “Spinal Stenosis Devices Market Insights, Competitive Landscape and Market Forecast-2030” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Spinal Stenosis Devices companies actively working in the market.

To know more about why North America is leading the market growth in the Spinal Stenosis Devices market, get a snapshot of the report Spinal Stenosis Devices Market Trends

https://www.delveinsight.com/report-store/spinal-stenosis-devices-market

Spinal Stenosis Devices Overview

Spinal Stenosis Devices are medical devices designed to treat spinal stenosis, a condition where the spaces within the spine narrow, putting pressure on the spinal cord and nerves. These devices include surgical instruments, implants, and braces used during procedures like decompression surgery, spinal fusion, or minimally invasive surgeries. They aim to relieve pain, improve mobility, and prevent further nerve damage by stabilizing the spine or decompressing the affected areas. Examples include spinal rods, screws, and intervertebral spacers.

DelveInsight Analysis: The global spinal stenosis devices market size was valued at USD 3,122.95 million in 2023 and is expected to grow at a CAGR of 4.83% from 2024 to 2030, reaching USD 4,131.08 million by 2030.

Spinal Stenosis Devices Market Insights

Geographically, In 2021, North America accounted for the largest share of 59.57% in the spinal stenosis devices market. The primary driver of this growth is the consistent increase in spinal stenosis cases caused by spinal injuries and osteoarthritis. Osteoarthritis, particularly prevalent among women and the elderly, is a significant health concern, driving the market’s expansion. According to the Centers for Disease Control and Prevention (CDC) in 2021, over 32.5 million adults in the US are affected by OA.

To read more about the latest highlights related to Spinal Stenosis Devices, get a snapshot of the key highlights entailed in the Spinal Stenosis Devices

Recent Developments in the Spinal Stenosis Devices Market Report

• In December 2021, Spinal Simplicity, a medical device company, revealed that the FDA has granted Indication for Use (IFU) approval for its Minuteman implant line to treat lumbar spinal stenosis.

• In October 2020, Stryker announced the full launch of the Niagara Lateral Access System, marking the expansion of its lateral spine portfolio, after successfully completing 600 surgeries.

• In June 2019, Boston Scientific Corporation announced the completion of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect Decompression System. This minimally invasive device is designed to enhance physical function and alleviate pain in patients with lumbar spinal stenosis (LSS), a condition where the narrowing of the spinal canal causes nerve compression.

• Thus, owing to such developments in the market, rapid growth will be observed in the Spinal Stenosis Devices market during the forecast period

Key Players in the Spinal Stenosis Devices Market

Some of the key market players operating in the Spinal Stenosis Devices market include- Spinal Simplicity, Boston Scientific Corporation, Medtronic, Stryker, Surgalign, Zimmer Biomet, NuVasive Inc., Sintea Plustek LLC, Orthofix Medical Inc., Globus Medical, Alphatec Holdings, Inc., Johnson & Johnson, NEO-MEDICAL SA, Premia Spine, ulrich GmbH & Co. KG, B. Braun Melsungen AG, Spineart, Meril Life Sciences Pvt. Ltd., Empirical Spine, Inc., Empirical Spine, Inc., Cousin Surgery, and others.

Which MedTech key players in the Spinal Stenosis Devices market are set to emerge as the trendsetter explore @ Key Spinal Stenosis Devices Companies

COVID-19 Impact Analysis on the Spinal Stenosis Devices Market

The increasing incidence of spinal injuries, caused by factors such as traumatic events, road accidents, sports injuries, and falls, is expected to be a major driver of the spinal stenosis devices market.

Additionally, The COVID-19 pandemic initially had a slightly negative effect on the growth of the spinal stenosis devices market due to lockdowns, border closures, and other disruptions that affected manufacturing, supply, import, export, and related activities. Additionally, the fear of spreading the SARS-CoV-2 virus led many countries to close spine clinics and specialty centers, except for emergency cases. However, with the resumption of activities across various industries, including healthcare, the spinal stenosis devices market has seen an uplift and is expected to experience growth during the forecast period from 2024 to 2030.

Scope of the Spinal Stenosis Devices Market Report

• Coverage: Global

• Study Period: 2020–2030

• Spinal Stenosis Devices Market Segmentation By Product Type: (Interspinous Spacers, Stabilization Systems, Spinal Arthroplasty Systems, And Interbody Fusion Devices), And Others

• Spinal Stenosis Devices Market Segmentation By Application Type: (Lumbar Spinal Stenosis, Cervical Spinal Stenosis, And Thoracic Spinal Stenosis), and others

• Spinal Stenosis Devices Market Segmentation By End-User: Hospitals, Ambulatory Surgical Centres, and others

• Spinal Stenosis Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Spinal Stenosis Devices Companies: Spinal Simplicity, Boston Scientific Corporation, Medtronic, Stryker, Surgalign, Zimmer Biomet, NuVasive Inc., Sintea Plustek LLC, Orthofix Medical Inc., Globus Medical, Alphatec Holdings, Inc., Johnson & Johnson, NEO-MEDICAL SA, Premia Spine, ulrich GmbH & Co. KG, B. Braun Melsungen AG, Spineart, Meril Life Sciences Pvt. Ltd., Empirical Spine, Inc., Empirical Spine, Inc., Cousin Surgery, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Spinal Stenosis Devices market will grow by 2030? Click to get a snapshot of the Spinal Stenosis Devices Market Analysis

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Spinal Stenosis Devices Market to reach USD 4,131.08 million at a CAGR of 4.83% by 2030, Evaluates DelveInsight | Spinal Simplicity, Boston Scientific Corporation, Medtronic, Stryker, Surgalig

DelveInsight’s “PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034″ report offers an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology as well as the PCSK9 Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the PCSK9 Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PCSK9 Inhibitors Market Forecast

Some of the key facts of the PCSK9 Inhibitors Market Report:

• The PCSK9 Inhibitors market size was valued ~USD 2,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2025, AstraZeneca’s PURSUIT Phase IIb trial for AZD0780 showed positive results, with a statistically significant reduction in low-density lipoprotein cholesterol (LDL-C) when combined with standard statin therapy, compared to placebo. AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients not achieving their LDL-C lowering targets with standard lipid-lowering treatments like statins.

• In May 2024, LIB Therapeutics reported positive outcomes from two studies in the recently concluded Phase III LIBerate registration-enabling program at the 92nd European Atherosclerosis Society Congress in Lyon, France, held from May 26-29, 2024.

• In May 2024, AstraZeneca revealed Phase I trial results for its PCSK9 inhibitor, AZD0780, demonstrating a statistically significant decrease in low-density lipoprotein cholesterol levels in patients with hypercholesterolemia.

• Currently, two FDA-approved monoclonal antibodies that block the action of PCSK9 are PRALUENT (alirocumab) and REPATHA (evolocumab). Recently, both the European Union and the FDA approved LEQVIO (inclisiran), a small interfering mRNA that prevents the intracellular production of PCSK9.

• In the United States, there were approximately 1,490,000 prevalent instances of FH in 2021, and this figure is anticipated to rise from 2020 to 2034

• According to Hemphill et al. (2020), low-density lipoprotein (LDL) receptor gene mutations are the most frequent cause of homozygous familial hypercholesterolemia (HoFH), an inherited condition

• Around 1,275,000 instances of FH were widespread overall in EU-5 in 2021; this number is projected to rise from 2020 to 2034

• The overall number of prevalent FH cases in Japan was at 363,700 in 2021, and it is anticipated that this number will rise from 2020 to 2034

• Key PCSK9 Inhibitors Companies: Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, AstraZeneca and Ionis Pharmaceuticals, CiVi Biopharma, and others

• Key PCSK9 Inhibitors Therapies: STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others

• The PCSK9 Inhibitors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PCSK9 Inhibitors pipeline products will significantly revolutionize the PCSK9 Inhibitors market dynamics.

PCSK9 Inhibitors Overview

An enzyme called proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, preventing LDL from being excreted from the blood and causing blood levels of LDL to rise. As a result of the PCSK9 inhibitor’s blocking of the PCSK9 enzyme, there are more LDL receptors available to remove LDL from the blood, which lowers blood levels of LDL.

Get a Free sample for the PCSK9 Inhibitors Market Report:

https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

PCSK9 Inhibitors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

PCSK9 Inhibitors Epidemiology Segmentation:

The PCSK9 Inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of PCSK9 Inhibitors

• Prevalent Cases of PCSK9 Inhibitors by severity

• Gender-specific Prevalence of PCSK9 Inhibitors

• Diagnosed Cases of Episodic and Chronic PCSK9 Inhibitors

Download the report to understand which factors are driving PCSK9 Inhibitors epidemiology trends @ PCSK9 Inhibitors Epidemiology Forecast

PCSK9 Inhibitors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PCSK9 Inhibitors market or expected to get launched during the study period. The analysis covers PCSK9 Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the PCSK9 Inhibitors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

PCSK9 Inhibitors Therapies and Key Companies

• STP135G: Sirnaomics

• PCSK9 inhibitor: Vaxxinity

• VERVE 101: Verve Therapeutics

• SAL-003: Xinlitai Biotechnology

• NNC 03850434: Novo Nordisk

• AZD 8233: AstraZeneca

• AK102: Akeso Biopharma

• Evolocumab: Amgen

• SHR-1209: Jiangsu Hengrui Medicine Co.

• Tafolecimab: Innovent Biologics

• LIB003 (Lerodalcibep): LIB Therapeutics

• AZD8233 (ION449): AstraZeneca and Ionis Pharmaceuticals

• Cepadacursen sodium (CIVI-007): CiVi Biopharma

• CiVI-008: CiVi Biopharma

Discover more about therapies set to grab major PCSK9 Inhibitors market share @ PCSK9 Inhibitors Treatment Market

PCSK9 Inhibitors Market Strengths

• According to the World Heart Federation report, CVD alone, including heart disease and stroke, makes up nearly 50% of all non-communicable disease deaths. Prevention of CVD in high-risk patients by PCSK9 inhibition might help in relieving the high economic burden.

PCSK9 Inhibitors Market Opportunities

• Though monoclonal antibodies have, for the time being, established themselves as the most clinically useful inhibitors of PCSK9, other novel therapies are currently in various stages of development.

Scope of the PCSK9 Inhibitors Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key PCSK9 Inhibitors Companies: Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso Biopharma, Amgen, Jiangsu Hengrui Medicine Co., Innovent Biologics, LIB Therapeutics, AstraZeneca and Ionis Pharmaceuticals, CiVi Biopharma, and others

• Key PCSK9 Inhibitors Therapies: STP135G, PCSK9 inhibitor, VERVE 101, SAL-003, NNC 03850434, AZD 8233, AK102, Evolocumab, SHR-1209, Tafolecimab, LIB003 (Lerodalcibep), AZD8233 (ION449), Cepadacursen sodium (CIVI-007), CiVI-008, and others PCSK9 Inhibitors Therapeutic Assessment: PCSK9 Inhibitors current marketed and PCSK9 Inhibitors emerging therapies

• PCSK9 Inhibitors Market Dynamics: PCSK9 Inhibitors market drivers and PCSK9 Inhibitors market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• PCSK9 Inhibitors Unmet Needs, KOL’s views, Analyst’s views, PCSK9 Inhibitors Market Access and Reimbursement

To know more about PCSK9 Inhibitors companies working in the treatment market, visit @ PCSK9 Inhibitors Clinical Trials and Therapeutic Assessment

Table of Contents

1. PCSK9 Inhibitors Market Report Introduction

2. Executive Summary for PCSK9 Inhibitors

3. SWOT analysis of PCSK9 Inhibitors

4. PCSK9 Inhibitors Patient Share (%) Overview at a Glance

5. PCSK9 Inhibitors Market Overview at a Glance

6. PCSK9 Inhibitors Disease Background and Overview

7. PCSK9 Inhibitors Epidemiology and Patient Population

8. Country-Specific Patient Population of PCSK9 Inhibitors

9. PCSK9 Inhibitors Current Treatment and Medical Practices

10. PCSK9 Inhibitors Unmet Needs

11. PCSK9 Inhibitors Emerging Therapies

12. PCSK9 Inhibitors Market Outlook

13. Country-Wise PCSK9 Inhibitors Market Analysis (2020–2034)

14. PCSK9 Inhibitors Market Access and Reimbursement of Therapies

15. PCSK9 Inhibitors Market Drivers

16. PCSK9 Inhibitors Market Barriers

17. PCSK9 Inhibitors Appendix

18. PCSK9 Inhibitors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PCSK9 Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sirnaomics, Vaxxinity, Verve Therapeutics, Xinlitai Biotechnology, Novo Nordisk, AstraZeneca, Akeso

DelveInsight’s “Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Polymyalgia Rheumatica, historical and forecasted epidemiology as well as the Polymyalgia Rheumatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Polymyalgia Rheumatica market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyalgia Rheumatica Market Forecast

Some of the key facts of the Polymyalgia Rheumatica Market Report:

• The Polymyalgia Rheumatica market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In November 2024, Sparrow Pharmaceuticals, a clinical-stage biopharma company focused on developing targeted therapies for unmet needs in endocrinology and rheumatology, will present interim results from its ongoing Phase 2 trial of its lead candidate, clofutriben—a potent, selective HSD-1 inhibitor—combined with prednisolone for treating polymyalgia rheumatica (PMR) at the American College of Rheumatology Convergence 2024, held November 14–19 at the Walter E. Washington Convention Center in Washington, D.C. Additionally, Sparrow announced the expansion of the trial with a fifth cohort, following promising outcomes from the first four cohorts.

• According to Duncan et al. the estimated prevalence of PMR, in the United States, is 1 in

• 133 people over the age of 50 years. The incidence of PMR and GCA increases with age, with a peak in those 70–80 years of age

• According to Crowson ‘et al’ women accounted for 65 to 75% of patients. Polymyalgia rheumatica occurs at a frequency that is 3 to 10 times that of giant-cell arteritis

• Key Polymyalgia Rheumatica Companies: Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek, and others

• Key Polymyalgia Rheumatica Therapies: Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab, and others

• The Polymyalgia Rheumatica epidemiology based on gender analyzed that the prevalence of Polymyalgia Rheumatica (PMR) is more among females as compared to males

• The Polymyalgia Rheumatica market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyalgia Rheumatica pipeline products will significantly revolutionize the Polymyalgia Rheumatica market dynamics.

Polymyalgia Rheumatica Overview

Polymyalgia rheumatica (PMR) is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). PMR can be a relatively benign condition that is extremely responsive to treatment.

Get a Free sample for the Polymyalgia Rheumatica Market Report

https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market

Polymyalgia Rheumatica Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polymyalgia Rheumatica Epidemiology Segmentation:

The Polymyalgia Rheumatica market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Polymyalgia Rheumatica

• Prevalent Cases of Polymyalgia Rheumatica by severity

• Gender-specific Prevalence of Polymyalgia Rheumatica

• Diagnosed Cases of Episodic and Chronic Polymyalgia Rheumatica

Download the report to understand which factors are driving Polymyalgia Rheumatica epidemiology trends @ Polymyalgia Rheumatica Epidemiology Forecast

Polymyalgia Rheumatica Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyalgia Rheumatica market or expected to get launched during the study period. The analysis covers Polymyalgia Rheumatica market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyalgia Rheumatica Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polymyalgia Rheumatica Therapies and Key Companies

• Tocilizumab: Roche

• Abatacept: Bristol Myers Squibb

• Baricitinib: Eli-lilly

• Secukinumab: Novartis

• ABBV-154: AbbVie

• SPI-62: Sparrow Pharmaceuticals

• TCZ: Chugai Pharma

• Upadacitinib: AbbVie

• Guselkumab: Janssen Research & Development

• Rituximab: Sint Maartenskliniek

Discover more about therapies set to grab major Polymyalgia Rheumatica market share @ Polymyalgia Rheumatica Treatment Market

Scope of the Polymyalgia Rheumatica Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Polymyalgia Rheumatica Companies: Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek, and others

• Key Polymyalgia Rheumatica Therapies: Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab, and others

• Polymyalgia Rheumatica Therapeutic Assessment: Polymyalgia Rheumatica current marketed and Polymyalgia Rheumatica emerging therapies

• Polymyalgia Rheumatica Market Dynamics: Polymyalgia Rheumatica market drivers and Polymyalgia Rheumatica market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Polymyalgia Rheumatica Unmet Needs, KOL’s views, Analyst’s views, Polymyalgia Rheumatica Market Access and Reimbursement

To know more about Polymyalgia Rheumatica companies working in the treatment market, visit @ Polymyalgia Rheumatica Clinical Trials and Therapeutic Assessment

Table of Contents

1. Polymyalgia Rheumatica Market Report Introduction

2. Executive Summary for Polymyalgia Rheumatica

3. SWOT analysis of Polymyalgia Rheumatica

4. Polymyalgia Rheumatica Patient Share (%) Overview at a Glance

5. Polymyalgia Rheumatica Market Overview at a Glance

6. Polymyalgia Rheumatica Disease Background and Overview

7. Polymyalgia Rheumatica Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyalgia Rheumatica

9. Polymyalgia Rheumatica Current Treatment and Medical Practices

10. Polymyalgia Rheumatica Unmet Needs

11. Polymyalgia Rheumatica Emerging Therapies

12. Polymyalgia Rheumatica Market Outlook

13. Country-Wise Polymyalgia Rheumatica Market Analysis (2019–2032)

14. Polymyalgia Rheumatica Market Access and Reimbursement of Therapies

15. Polymyalgia Rheumatica Market Drivers

16. Polymyalgia Rheumatica Market Barriers

17. Polymyalgia Rheumatica Appendix

18. Polymyalgia Rheumatica Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polymyalgia Rheumatica Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharma, Chugai Pharma, AbbVie

DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Eosinophilic Esophagitis, historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Eosinophilic Esophagitis Market Forecast

Some of the key facts of the Eosinophilic Esophagitis Market Report:

• The Eosinophilic Esophagitis market size was valued approximately USD 1,800 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In February 2025, Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech firm focused on precision local drug delivery, today shared further positive clinical results from its ongoing RESOLVE Phase 1b/2a trial, which is assessing EP-104GI for the treatment of eosinophilic esophagitis (EoE).

• In December 2024, Holoclara, a biotech firm focused on worm-derived therapies for allergic and autoimmune diseases, has chosen eosinophilic esophagitis (EoE) as the primary indication for its investigational drug, HC002, with plans to expand to other conditions. The company is currently conducting a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of HC002 in healthy adults.

• In December 2024, Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotech company developing innovative biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE), has announced the start of dosing healthy volunteers in its clinical trial of APG333. This novel, subcutaneous monoclonal antibody, with a half-life extension, targets thymic stromal lymphopoietin (TSLP) and is initially being evaluated as a treatment for asthma, COPD, and other I&I disorders.

• In September 2024, Regeneron Pharmaceuticals and Sanofi revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the expanded approval of DUPIXENT (dupilumab) for eosinophilic esophagitis (EoE) in children as young as 1 year old in the European Union. The recommendation applies to children aged 1–11 years who weigh at least 15 kg. A final decision from the European Commission is expected in the coming months.a

• The US accounted for Eosinophilic Esophagitis for USD 805 million in 2023 and is expected to rise by 2034.

• In the EU4 and the UK, Germany leads with the largest market size of roughly USD 21 billion, trailed by France and the UK with approximately USD 19 billion and USD 17 billion, respectively. These figures are anticipated to fluctuate throughout the forecast period (2024-2034) due to continued research and development endeavors, potentially resulting in the identification of more efficacious medications and treatments for managing Eosinophilic Esophagitis.

• In January 2024, The US FDA granted approval for DUPIXENT (dupilumab) to treat pediatric patients between the ages of 1 and 11 years, weighing at least 15 kg, who have eosinophilic esophagitis (EoE). This approval stems from the Phase III EoE KIDS trial, which demonstrated that a higher percentage of children receiving DUPIXENT achieved histological remission compared to those receiving a placebo.

• There are few approved medications available in the market to treat eosinophilic esophagitis (EoE), including DUPIXENT (dupilumab) and JORVEZA (budesonide).

• In 2023, the US had the highest number of diagnosed prevalent cases of Eosinophilic Esophagitis in the 7MM, with approximately 445,000 cases. This figure is expected to rise throughout the forecast period.

• In 2023, Eosinophilic Esophagitis predominantly affected males in the US, with around 290,000 male cases compared to 156,000 female cases.

• In the 7MM, individuals aged 18 and above were the most impacted by Eosinophilic Esophagitis, with roughly 156,000 cases reported in 2023.

• Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others

• Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others

• The Eosinophilic Esophagitis epidemiology based on gender analyzed that Eosinophilic Esophagitis affects more males as compared to females

• The Eosinophilic Esophagitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Esophagitis pipeline products will significantly revolutionize the Eosinophilic Esophagitis market dynamics.

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition that affects the esophagus, the tube that connects the mouth to the stomach. In EoE, the esophagus becomes inflamed due to an allergic reaction to certain foods, environmental allergens, or other triggers. This inflammation leads to the accumulation of eosinophils, a type of white blood cell, in the esophageal tissue, causing symptoms such as difficulty swallowing, chest pain, food impaction, and heartburn.

Get a Free sample for the Eosinophilic Esophagitis Market Report:

https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market

Eosinophilic Esophagitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Eosinophilic Esophagitis Epidemiology Segmentation:

The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Eosinophilic Esophagitis

• Prevalent Cases of Eosinophilic Esophagitis by severity

• Gender-specific Prevalence of Eosinophilic Esophagitis

• Diagnosed Cases of Episodic and Chronic Eosinophilic Esophagitis

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Epidemiology Forecast

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Esophagitis market or expected to get launched during the study period. The analysis covers Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Eosinophilic Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Eosinophilic Esophagitis Therapies and Key Companies

• Dupilumab: Regeneron Pharmaceuticals/Sanofi

• Cendakimab: Bristol-Myers Squibb

• APT-1011: Ellodi Pharmaceuticals

• Benralizumab: AstraZeneca

• Lirentelimab: Allakos

• ESO-101: EsoCap AG

• Etrasimod: Pfizer

• reslizumab: Ception Therapeutics

• CC-93538: Celgene

• Mesalamine: Dr. Falk Pharma GmbH

• IRL201104: Revolo Biotherapeutics

• budesonide: Shire

• QAX576: Novartis

• Florence: EMS

• RPC4046: Celgene

• OC000459: Oxagen Ltd

• Budesonide plus Prevacid: Meritage Pharma, Inc

• EUR-1100: Forest Laboratories

Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ Eosinophilic Esophagitis Treatment Market

Scope of the Eosinophilic Esophagitis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others

• Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others

• Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies

• Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Eosinophilic Esophagitis Unmet Needs, KOL’s views, Analyst’s views, Eosinophilic Esophagitis Market Access and Reimbursement

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Eosinophilic Esophagitis Market Report Introduction

2. Executive Summary for Eosinophilic Esophagitis

3. SWOT analysis of Eosinophilic Esophagitis

4. Eosinophilic Esophagitis Patient Share (%) Overview at a Glance

5. Eosinophilic Esophagitis Market Overview at a Glance

6. Eosinophilic Esophagitis Disease Background and Overview

7. Eosinophilic Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Eosinophilic Esophagitis

9. Eosinophilic Esophagitis Current Treatment and Medical Practices

10. Eosinophilic Esophagitis Unmet Needs

11. Eosinophilic Esophagitis Emerging Therapies

12. Eosinophilic Esophagitis Market Outlook

13. Country-Wise Eosinophilic Esophagitis Market Analysis (2020–2034)

14. Eosinophilic Esophagitis Market Access and Reimbursement of Therapies

15. Eosinophilic Esophagitis Market Drivers

16. Eosinophilic Esophagitis Market Barriers

17. Eosinophilic Esophagitis Appendix

18. Eosinophilic Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eosinophilic Esophagitis Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap

The Colorectal Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Colorectal Cancer pipeline products will significantly revolutionize the Colorectal Cancer market dynamics.

DelveInsight’s “Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Colorectal Cancer, historical and forecasted epidemiology as well as the Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Colorectal Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Colorectal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Colorectal Cancer Market Insights

Some of the key facts of the Colorectal Cancer Market Report:

• The Colorectal Cancer market size was valued ~USD 13,000 million in 2023 and is anticipated to grow with a significant CAGR of 5% during the study period (2020-2034)

• In February 2025, Pfizer’s combination therapy for metastatic colorectal cancer (mCRC) achieved one of its main goals—enhancing progression-free survival (PFS)—in a Phase III clinical trial, reinforcing the potential for full regulatory approval. The BREAKWATER trial (NCT05217446), an open-label, active-controlled study, assessed a regimen combining Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab), and the chemotherapy mix mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin). The trial focused on treatment-naive mCRC patients with a BRAF V600E mutation.

• In February 2025, Averto Medical revealed that the FDA has awarded Breakthrough Device Designation to its ColoSeal™ Intraluminal Colonic Diversion (ICD) System. This innovative device is designed to enhance recovery and outcomes for colorectal surgery patients by potentially eliminating the requirement for a temporary ostomy.

• In January 2025, The FDA granted approval for Amgen’s KRAS G12C inhibitor, Lumakras, to be used in combination with Vectibix for the treatment of advanced colorectal cancer.

• In December 2024, EndoQuest Robotics gained FDA IDE approval for a clinical trial to evaluate its surgical robot in colorectal lesion removal. The trial will involve 50 participants across five US sites, focusing on the safety and performance of the system in ESD procedures (NCT06133387).

• In October 2024, U.S. regulators have prolonged their evaluation of Amgen’s LUMAKRAS (sotorasib) for second-line colorectal cancer (CRC) by three months, delaying a possible approval decision until January 17 of next year. This extension also temporarily reduces competitive pressure on Bristol Myers Squibb’s competing KRAS-inhibitor, KRAZATI (adagrasib).

• In June 2024, Bristol Myers Squibb announced US FDA accelerated approval of KRAZATI (adagrasib) in combination with cetuximab for adult patients with previously treated kras G12C-mutated locally advanced or metastatic colorectal cancer.

• In April 2024, ENHERTU was approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours, including colorectal cancer.

• Colorectal cancer is the third most frequently diagnosed cancer globally. In 2024, the United States is expected to report around 106,600 new cases of the disease. It remains the second leading cause of cancer-related deaths in the country for both men and women.

• In 2023, the United States represented approximately 30% of all newly diagnosed cases of colorectal cancer across the 7MM.

• In 2023, around 68,400 cases of colorectal cancer were reported in the United States among individuals aged 65-84 years.

• In 2023, approximately 52,000 cases of colorectal cancer were found in the right colon in the United States.

• The Surveillance, Epidemiology, and End Results (SEER) program published age and gender data for colorectal cancer patients. According to the registry, the distribution of cases by stage was as follows: 38% localized, 35% regional, 22% distant, and 4% unknown.

• Key Colorectal Cancer Companies: Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others

• Key Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), Niraparib, QL1706, Nivolumab, SGM-101, tucatinib, GRT-C901, Pembrolizumab, BXQ-350, Radspherin, MRTX849, Revumenib, Onvansertib, DKN-01, XL092, Atezolizumab, Nanrilkefusp alfa, pTTL, AK119, MRTX849,and others

• The Colorectal Cancer epidemiology based on gender analyzed that Colorectal Cancer is more common in men as compared to women

Colorectal Cancer Overview

Colorectal cancer is a type of cancer that begins in the colon or rectum, parts of the large intestine. It typically starts as small, non-cancerous growths called polyps, which can develop into cancer over time. The exact cause of colorectal cancer is unclear, but risk factors include age, family history, certain genetic conditions, and lifestyle factors like diet, smoking, and lack of physical activity. Symptoms may include changes in bowel habits, blood in stool, abdominal pain, and unexplained weight loss. Early detection through screening, such as colonoscopy, is key to improving outcomes, as treatment options like surgery, chemotherapy, and radiation can be effective when the cancer is caught early.

Get a Free sample for the Colorectal Cancer Market Report:

https://www.delveinsight.com/report-store/colorectal-cancer-crc-market

Colorectal Cancer Market

The dynamics of the Colorectal Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“According to the estimates, the highest market size of Colorectal Cancer was found in the United States, followed by Japan and the least was in Spain across the 7MM in 2021. Besides, the upcoming therapies of Colorectal Cancer are expected to combat the current unmet needs faced by the patients with Colorectal Cancer and add to the overall growth of the Colorectal Cancer market size.”

Colorectal Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Colorectal Cancer Epidemiology Segmentation:

The Colorectal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Colorectal Cancer

• Prevalent Cases of Colorectal Cancer by severity

• Gender-specific Prevalence of Colorectal Cancer

• Diagnosed Cases of Episodic and Chronic Colorectal Cancer

Download the report to understand which factors are driving Colorectal Cancer epidemiology trends @ Colorectal Cancer Epidemiological Insights

Colorectal Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Colorectal Cancer market or expected to get launched during the study period. The analysis covers Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Colorectal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Colorectal Cancer Therapies and Key Companies

• FRUZAQLA (fruquintinib): Takeda

• TUKSYA (tucatinib): Genentech/Seagen

• ENHERTU (trastuzumab deruxtecan): AstraZeneca and Daiichi Sankyo

• Favezelimab + pembrolizumab: Merck

• LUMAKRAS (sotorasib): Amgen

• Niraparib: Ibrahim Halil Sahin

• QL1706: Qilu Pharmaceutical

• Nivolumab: Bristol-Myers Squibb

• SGM-101: Surgimab

• tucatinib: Seagen Inc.

• GRT-C901: Gritstone bio, Inc.

• Pembrolizumab: Merck Sharp & Dohme

• BXQ-350: Bexion Pharmaceuticals

• Radspherin: Oncoinvent AS

• MRTX849: Mirati Therapeutics

• Revumenib: Syndax Pharmaceuticals

• Onvansertib: Cardiff Oncology

• DKN-01: Leap Therapeutics, Inc.

• XL092: Exelixis

• Atezolizumab: AIO-Studien-gGmbH

• Nanrilkefusp alfa: SOTIO Biotech AG

• pTTL: Neogap Therapeutics AB

• AK119: Akeso

• MRTX849: Mirati Therapeutics Inc.

To know more about Colorectal Cancer treatment, visit @ Colorectal Cancer Medications

Colorectal Cancer Market Strengths

• Recent advances in pathological staging and identification of the mutational status of KRAS (exon2), BRAF (V600E), and PIK3CA have greatly helped in deciding a path for anti-EGFR therapy of mCRC patients

Colorectal Cancer Market Opportunities

• The recent inclination toward the development of mutation-specific mCRC therapies has led to the approvals of KEYTRUDA, OPDIVO with or without YERVOY and BRAFTOVI in combination with ERBITUX. This clearly, opens up a window for several upcoming mutation-targeted therapies to enter and capture the market

Scope of the Colorectal Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Colorectal Cancer Companies: Takeda, Genentech/Seagen, AstraZeneca and Daiichi Sankyo, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others, and others

• Key Colorectal Cancer Therapies: FRUZAQLA (fruquintinib), TUKSYA (tucatinib), ENHERTU (trastuzumab deruxtecan), Favezelimab + pembrolizumab, LUMAKRAS (sotorasib), Niraparib, QL1706, Nivolumab, SGM-101, tucatinib, GRT-C901, Pembrolizumab, BXQ-350, Radspherin, MRTX849, Revumenib, Onvansertib, DKN-01, XL092, Atezolizumab, Nanrilkefusp alfa, pTTL, AK119, MRTX849, and others

• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies

• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Colorectal Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Colorectal Cancer market share @ Colorectal Cancer Treatment Landscape

Table of Contents

1. Colorectal Cancer Market Report Introduction

2. Executive Summary for Colorectal Cancer

3. SWOT analysis of Colorectal Cancer

4. Colorectal Cancer Patient Share (%) Overview at a Glance

5. Colorectal Cancer Market Overview at a Glance

6. Colorectal Cancer Disease Background and Overview

7. Colorectal Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Colorectal Cancer

9. Colorectal Cancer Current Treatment and Medical Practices

10. Colorectal Cancer Unmet Needs

11. Colorectal Cancer Emerging Therapies

12. Colorectal Cancer Market Outlook

13. Country-Wise Colorectal Cancer Market Analysis (2020–2034)

14. Colorectal Cancer Market Access and Reimbursement of Therapies

15. Colorectal Cancer Market Drivers

16. Colorectal Cancer Market Barriers

17. Colorectal Cancer Appendix

18. Colorectal Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Genentech/Seagen, AstraZeneca, Merck, Amgen, Daiichi Sankyo Company, Mirati Therapeutics

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

Some of the key facts of the Knee Osteoarthritis Market Report:

• The Knee Osteoarthritis market size was valued ~USD 14, 400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.

• In September 2024, Cytonics announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.

• Among the 7MM, the US holds the largest market size for knee osteoarthritis (OA). This growth is driven by the emergence of new therapies, with the market size for knee OA estimated to be around USD 8,900 million in 2023.

• In May 2024, Organogenesis reported encouraging topline results from a Phase III randomized controlled trial assessing the safety and effectiveness of ReNu in managing symptoms of knee osteoarthritis.

• In 2023, the US recorded the highest number of prevalent cases, totaling approximately 18,499,200, followed by Japan.

• In the US, the age group of 70 years and older represented the highest number of cases in 2023, while the lowest number of cases was observed in the 18–39 age group.

• A study by Yokota et al. (2023) indicates that knee osteoarthritis is highly prevalent in Japan, affecting an estimated 25.3 million individuals over the age of 40, with around 8 million experiencing symptomatic cases.

• In 2023, there were approximately 97 million diagnosed cases of knee osteoarthritis in the 7MM. This number is expected to rise during the forecast period from 2024 to 2034.

• In 2023, within the EU4 and the UK, the highest proportion of age-specific knee osteoarthritis cases were observed in individuals aged 70 and above, followed by those in the 60-69 and 50-59 age groups.

• Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others

• Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others

• The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Knee osteoarthritis (OA) is a degenerative joint disease where the cartilage in the knee deteriorates over time, causing pain, stiffness, swelling, and reduced mobility. It is commonly associated with aging, injury, or overuse, leading to the wear and tear of the knee joint. Symptoms can range from mild discomfort to severe disability, often affecting daily activities.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Knee Osteoarthritis

• Prevalent Cases of Knee Osteoarthritis by severity

• Gender-specific Prevalence of Knee Osteoarthritis

• Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

• TLC599: Taiwan Liposome Company

• CNTX-4975: Centrexion Therapeutics

• Lorecivivint (SM04690): Biosplice Therapeutic

• HP-5000: Noven Pharmaceuticals

• Invossa (TG-C): Kolon TissueGene

• ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals

• ReNu (Amniotic Suspension Allograft): Organogenesis

• JTA-004: BioSenic (Bone Therapeutics)

• Resiniferatoxin: Sorrento Therapeutics, Inc.

• ICM-203: ICM Biotech Australia

• RTX-GRT7039: Grünenthal GmbH

• StroMel: Akan Biosciences, LLC

• GSK3858279: GlaxoSmithKline

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

Knee Osteoarthritis Market Strengths

• New approaches to osteoarthritis therapy currently being investigated include attempts to identify disease-modifying osteoarthritis drugs, tissue engineering for reconstituting intact cartilage and joint tissues, and biomechanically active methods for reducing aberrant loading in osteoarthritis-involved joints.

• Single injection joint function enhancing hyaluronic acid formulation’s sales are steadily rising, and companies are looking to expand into new markets to increase their single injection product profit.

Knee Osteoarthritis Market Opportunities

• Disease-modifying osteoarthritis drugs (DMOADs) could offer new therapeutic targets to restore the quality and function of tissues affected by osteoarthritis.

• People eagerly await non-opioid options, and key players can target this lucrative market segment while others are developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others

• Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others

• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies

• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2020–2034)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17. Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Market to Expand Significantly by 2034, States DelveInsight Report | Paradigm Biopharma, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech